USANA Health Sciences, Inc (USNA) has reported an 8.70 percent fall in profit for the quarter ended Dec. 31, 2016. The company has earned $21.88 million, or $0.87 a share in the quarter, compared with $23.97 million, or $0.92 a share for the same period last year. Revenue during the quarter grew 8.73 percent to $252.90 million from $232.58 million in the previous year period. Gross margin for the quarter contracted 104 basis points over the previous year period to 81.68 percent. Total expenses were 87.41 percent of quarterly revenues, up from 84.89 percent for the same period last year. That has resulted in a contraction of 252 basis points in operating margin to 12.59 percent.
Operating income for the quarter was $31.84 million, compared with $35.14 million in the previous year period.
"While USANA finished the year with another quarter of solid top line and Associate growth, several initiatives we implemented during the fourth quarter resulted in net earnings at the lower end of our guidance," said Kevin Guest, chief executive officer. "The first of these initiatives was the successful transition of our China manufacturing operations to our new production facility, which is now fully operational. With this facility in place, we now have the production capacity that we need in China. A second initiative entailed us offering a growth incentive to our Associates around the world that positively contributed to our performance during the quarter. These initiatives are important to our business and have also helped us get off to a good start in 2017."
For fiscal year 2017, USANA Health Sciences, Inc forecasts revenue to be in the range of $1,040 million to $1,070 million. The company expects diluted earnings per share to be in the range of $3.80 to $4.10.
Working capital increases
USANA Health Sciences, Inc has recorded an increase in the working capital over the last year. It stood at $139.37 million as at Dec. 31, 2016, up 23.50 percent or $26.52 million from $112.85 million on Jan. 02, 2016. Current ratio was at 2.01 as on Dec. 31, 2016, up from 1.86 on Jan. 02, 2016.
Disclaimer: Please note that this is an auto-generated article. IRIS does not guarantee the accuracy, adequacy or completeness of any information and is not responsible for any errors or omissions or for the results obtained from the use of such information. IRIS especially states that it has no financial liability whatsoever to any user on account of the use of information provided on its website. For queries contact: [email protected]
